Ab­b­Vie eyes Hu­mi­ra match­ing move in­to pso­ri­at­ic arthri­tis for im­munol­o­gy fol­low-up Skyrizi

Phar­ma borg Ab­b­Vie hasn’t had many road­blocks on its path to dom­i­nance with megablock­buster Hu­mi­ra reg­u­lar­ly top­ping phar­ma’s best­seller list. But Hu­mi­ra’s days on top are num­bered, and Ab­b­Vie is mak­ing the case for new­er im­munol­o­gy meds like IL-23 Skyrizi to help take the sting out of a cost­ly 2023 patent cliff.

Help­ing that cause, Skyrizi best­ed place­bo in terms of re­duc­ing pso­ri­at­ic arthri­tis pa­tients’ symp­toms from base­line af­ter six months of treat­ment, ac­cord­ing to da­ta from two Phase III tri­als un­veiled Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER